New Zealand - English - Medsafe (Medicines Safety Authority)

pierre fabre medicament australia pty ltd - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg - soft gelatin capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg - soft gelatin capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide - first line treatment of advanced non-small cell lung cancer (nsclc) as a single agent or in combination

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20mg;   - capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20mg   excipient: gelatin iron oxide yellow macrogol 400 polysorbate 80 purified water   sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: vinorelbine pierre fabre is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: vinorelbine pierre fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; gelatin; polysorbate 80; macrogol 400; titanium dioxide; partially dehydrated liquid sorbitol; iron oxide yellow - non-small cell lung cancer: vinorelbine lrx is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lrx is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; partially dehydrated liquid sorbitol; gelatin; macrogol 400; polysorbate 80; titanium dioxide; iron oxide yellow - non-small cell lung cancer: vinorelbine lu is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: vinorelbine lu is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: purified water; polysorbate 80; iron oxide yellow; gelatin; titanium dioxide; macrogol 400; partially dehydrated liquid sorbitol - non-small cell lung cancer: velabine is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,breast cancer: velabine is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30mg;   - capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30mg   excipient: gelatin iron oxide red macrogol 400 polysorbate 80 purified water   sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - vinorelbine tartrate 110.8mg equivalent to vinorelbine 80mg;   - capsule - 80 mg - active: vinorelbine tartrate 110.8mg equivalent to vinorelbine 80mg   excipient: gelatin iron oxide yellow macrogol 400 polysorbate 80 purified water   sorbitol titanium dioxide - vinorelbine is indicated in adults over 18. for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.